Rylaze (Asparaginase Erwinia Chrysanthemi Drug Interactions
Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rylaze. Always confirm against the full prescribing information.
100 interactions
Abacavir
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Abacavir.
Level 2 evidence
Abatacept
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Abatacept.
Level 2 evidence
Abemaciclib
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Abemaciclib.
Level 2 evidence
Abiraterone
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Abiraterone.
Level 2 evidence
Acalabrutinib
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Acalabrutinib.
Level 2 evidence
Acamprosate
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Acamprosate.
Level 2 evidence
Acarbose
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Acarbose.
Level 2 evidence
Acebutolol
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Acebutolol.
Level 2 evidence
Aceclofenac
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Aceclofenac.
Level 2 evidence
Acetaminophen
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Acetaminophen.
Level 2 evidence
Acetazolamide
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Acetazolamide.
Level 2 evidence
Acetohydroxamic acid
The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Acetohydroxamic acid.
Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) has 847 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) has 2 major, 842 moderate, and 3 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Rylaze. Always confirm against the full prescribing information.